Healthcare Industry News: Glaucoma
News Release - May 25, 2006
Allergan Receives Pan European License for GANFORT(R) (LUMIGAN(R)/Timolol Combination) from European CommissionIRVINE, Calif.--(HSMN NewsFeed)--May 25, 2006--Allergan, Inc. (NYSE:AGN ) today announced that it has received the license from the European Commission to market GANFORT®, Allergan's LUMIGAN®/timolol combination product (bimatoprost/timolol ophthalmic solution) for the treatment of Glaucoma, in the European Union.
"We are extremely pleased with the European Commission's approval of GANFORT®, which enables Allergan to provide physicians and patients throughout Europe with a once-daily, highly-effective and well-tolerated form of combination therapy for Glaucoma," said Scott Whitcup, M.D., Allergan's Executive Vice President, Research and Development.
GANFORT® is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle Glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. A fixed combination of bimatoprost 0.03% and timolol maleate 0.5%, GANFORT® offers powerful IOP-lowering efficacy comparable to the free combination of these two agents, and greater efficacy than monotherapy with either agent used alone. GANFORT® also provides clinically important IOP control in a once-daily dose, which is important for enhancing patient compliance - a key factor in controlling Glaucoma, a leading cause of preventable blindness worldwide. In clinical trials, GANFORT® also had a superior tolerability profile, including 40 percent less hyperemia compared to bimatoprost monotherapy.
About Allergan, Inc.
Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical and medical device products worldwide. Allergan develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives.
This press release contains "forward-looking statements," including, among other statements, the statements by Dr. Whitcup, statements regarding research and development outcomes, efficacy, and market and product potential. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include general industry and pharmaceutical market conditions; general domestic and international economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents obtained by competitors; challenges inherent in product marketing such as the unpredictability of market acceptance for new pharmaceutical and biologic products and/or the acceptance of new indications for such products; domestic and foreign health care reforms; the timing and uncertainty of the research and development and regulatory processes; trends toward managed care and health care cost containment; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.
Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2005 Form 10-K and Allergan's Form 10-Q for the quarter ended March 31, 2006. Copies of Allergan's press releases and additional information about Allergan is available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 1-714-246-4636.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.